biostudies-literatureBrownlee SOctapharma342-348https://www.ebi.ac.uk/biostudies/studies/S-EPMC9680362biostudies-literatureUnknown14(4)<h4>Objective</h4>Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig^® treatment offered a tolerable and safe alternative treatment for immunodeficient patients.<h4>Methods</h4>A one-year prospective cohort study was conducted at a single center in Ottawa, Canada. Adult immunodeficient patients who reported previous intolerability, adverse events, or other difficulty to other 20% SCIG product(s) were recruited to start on 16.5% Cutaquig^®. Treatment tolerability, safety, and quality of life were observed and described.<h4>Results</h4>Seven out of ten patients tolerated Cutaquig^®. There were no serious or severe adverse events Hematology reportsCutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products.PMC9680362NACowan JKana'an MFCameron DWAllen CBrownlee SfalseCutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products.<h4>Objective</h4>Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig^® treatment offered a tolerable and safe alternative treatment for immunodeficient patients.<h4>Methods</h4>A one-year prospective cohort study was conducted at a single center in Ottawa, Canada. Adult immunodeficient patients who reported previous intolerability, adverse events, or other difficulty to other 20% SCIG product(s) were recruited to start on 16.5% Cutaquig^®. Treatment tolerability, safety, and quality of life were observed and described.<h4>Results</h4>Seven out of ten patients tolerated Cutaquig^®. There were no serious or severe adverse events 2022-01-01T00:00:00Z2022 Nov2025-04-19T00:35:08.899Z2025-02-19T04:37:30.316ZS-EPMC96803623641262810.3390/hematolrep14040048